pmid,title,journal,year,drug,disease
38895380,TYK2 as a novel therapeutic target in Alzheimer's Disease with TDP-43 inclusions.,bioRxiv : the preprint server for biology,2024,Baricitinib,Multiple Sclerosis
37828541,Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis.,Translational neurodegeneration,2023,Baricitinib,Multiple Sclerosis
37269741,JAK2/STAT5 inhibition protects mice from experimental autoimmune encephalomyelitis by modulating T cell polarization.,International immunopharmacology,2023,Baricitinib,Multiple Sclerosis
37189112,Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases.,Cell communication and signaling : CCS,2023,Baricitinib,Multiple Sclerosis
33927721,Baricitinib Ameliorates Experimental Autoimmune Encephalomyelitis by Modulating the Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway.,Frontiers in immunology,2021,Baricitinib,Multiple Sclerosis
33640999,COVID-19 illness and autoimmune diseases: recent insights.,Inflammation research : official journal of the European Histamine Research Society ... [et al.],2021,Baricitinib,Multiple Sclerosis
33403021,Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis.,Therapeutic advances in musculoskeletal disease,2020,Baricitinib,Multiple Sclerosis
32222877,JAK Inhibitors: Prospects in Connective Tissue Diseases.,Clinical reviews in allergy & immunology,2020,Baricitinib,Multiple Sclerosis
31360575,Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report.,Case reports in rheumatology,2019,Baricitinib,Multiple Sclerosis
